The LinkedIn post from Max carries weight since he
Post# of 154945
(Total Views: 436)
Posted On: 07/02/2025 12:14:41 AM
The LinkedIn post from Max carries weight since he is Cytodyn Senior Vice President and Head of Clinical Development. His wording isn't entirely clear. It is hard to imagine that testing PD-L1 in the new CRC trial is an option. I have to think that they will be testing everyone.
The question I think is what does he mean by "option". A followup question might be, will the DMSB see the PD-L1 data and if there is large upregulation, does that present an ethical imperative to add the option to add ICI treatment?
The question I think is what does he mean by "option". A followup question might be, will the DMSB see the PD-L1 data and if there is large upregulation, does that present an ethical imperative to add the option to add ICI treatment?
(10)
(0)CytoDyn Inc (CYDY) Stock Research Links
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.